ArticleJournal of cardiothoracic surgery2025
Small cell lung cancer: relationship with HLA-I alleles and gene mutation.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSmall cell lung cancer is the most malignant subtype of lung cancer and has a poor prognosis. However, the mechanism is not well understood. The aim of this study was to investigate the characteristics of gene mutation in small cell lung cancer patients and the differences in HLA-I alleles between small cell lung cancer patients and healthy controls, and to explore the effects of gene mutations and specific HLA-I alleles on small-cell lung cancer from the perspective of immune regulation.
methodsDifferences in HLA-I allele frequencies between the two groups were analyzed in a case-control study. Genetic testing was performed using target gene capture and sequencing method. The association between small cell lung cancer, HLA-I alleles, and gene mutation was analyzed by statistical methods.
resultsThe small cell lung cancer group showed significantly higher HLA-A*11:02 (p < 0.001, OR = 4.693, 95%CI = 1.737-12.677), B*40:01 (p = 0.020, OR = 1.916, 95%CI = 1.101-3.333), and B*55:02 (p = 0.037, OR = 2.565, 95%CI = 1.027-6.408) and significantly lower B*44:03 (p = 0.015, OR = 0.196, 95%CI = 0.046-0.843) and C*06:02 (p = 0.005, OR = 0.369, 95%CI = 0.178-0.765) than the control group. Haplotype analysis results showed that HLA-A*11:01-B*51:01 (p = 0.044, OR = 3.433, 95%CI = 0.959-12.292), A*02:06-C*07:02 (p = 0.005, OR = 11.459, 95%CI = 1.331-98.689), A*11:01-C*07:02 (p = 0.007, OR = 3.040, 95%CI = 1.311-7.047), and B*46:01-C*01:02 (p = 0.048, OR = 2.310, 95%CI = 0.986-5.415) frequencies significantly increased and A*02:01-B*13:02 (p = 0.036, OR < 0.001, 95%CI = 0.000-0.918) and B*13:02-C*06:02 (p = 0.009, OR = 0.108, 95%CI = 0.014-0.810) frequency significantly decreased in small cell lung cancer patients. Three-locus haplotype analysis showed that the differences between small cell lung cancer patients and controls were not statistically significant.
conclusionHLA-A*11:01, B*40:01, and B*55:02 may be the immune modulators associated with susceptibility and HLA-B*44:03 and C*06:02 act as the immune modulators associated with resistance of small cell lung cancer. Haplotypes HLA-A*11:01-B*51:01, A*02:06-C*07:02, A*11:01-C*07:02, and B*46:01-C*01:02 are positively associated with small cell lung cancer. Haplotypes A*02:01-B*13:02 and B*13:02-C*06:02 are negatively associated with small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.